Annexon Inc. (ANNX)
Annexon Inc. (ANNX) Stock Price, Analysis & Data
| Bid | 3.85 |
| Market Cap | 866.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -202.67M |
| Beta | 1.22 |
| EPS (ttm) | -1.13 |
| PE Ratio (ttm) | n/a |
| Forward PE | -4.88 |
| P/B (ttm) | 4.96 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 9, 2026 |
| Ask | 6.51 |
| Volume | 2,990,009 |
| Avg. Volume (20D) | 3,619,990 |
| Open | 5.23 |
| Previous Close | 5.26 |
| Day's Range | 5.08 - 5.34 |
| 52-Week Range | 2.03 - 7.18 |
| Analyst | Buy |
| Price Target | 12 (126.84%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic...
Financial Performance
In 2025, Annexon's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -206.69M, an increase of 49.56%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for ANNX stock is "Buy". The 12-month stock price forecast is 12, which is upside of 126.84% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
